Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy

Nature Reviews Nephrology

Volumn 12, Issue 10, 2016, Pages 583-584

  Yamout, Hala ^a   Bakris, George L ^b  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE KIDNEY FAILURE; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MECHANISM; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; PRIORITY JOURNAL; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; TREATMENT OUTCOME; URINARY TRACT INFECTION; DISEASE EXACERBATION;

DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84978524136     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2016.109     Document Type: Short Survey

References (10)

1. Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807-814 (2012).
2. Saran, R. et al. US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 67, A7-A8 (2016).
3. Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1515920 (2016).
4. Kalaitzidis, R. & Bakris, G. L. in Handbook of Chronic Kidney Disease Management (ed Daugirdas, J.) 224-239 (Lippincott, 2011).
5. Zoungas, S. et al. Follow?up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 371, 1392-1406 (2014).
6. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015).
7. Cherney, D. Z. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129, 587-597 (2014).
8. Tikkanen, I. et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38, 420-428 (2015).
9. Oliva, R. V. & Bakris, G. L. Blood pressure effects of sodium-glucose co?transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 8, 330-339 (2014).
10. Rafiq, K. et al. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia 58, 2885-2898 (2015).